Biocept, Inc.
BIOCQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -12.48% | 173.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.48% | 173.71% | |||
| Cost of Revenue | -15.79% | -29.71% | |||
| Gross Profit | 16.73% | 54.89% | |||
| SG&A Expenses | 1.11% | 10.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.74% | -12.45% | |||
| Operating Income | 13.86% | 27.49% | |||
| Income Before Tax | 49.17% | 27.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 49.17% | 26.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 49.17% | 26.41% | |||
| EBIT | 13.86% | 27.49% | |||
| EBITDA | 15.59% | 29.09% | |||
| EPS Basic | 71.20% | 28.74% | |||
| Normalized Basic EPS | 71.20% | 29.65% | |||
| EPS Diluted | 71.52% | 27.97% | |||
| Normalized Diluted EPS | 71.20% | 29.65% | |||
| Average Basic Shares Outstanding | 76.46% | 3.27% | |||
| Average Diluted Shares Outstanding | 76.46% | 3.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||